Trastuzumab (IV) Monotherapy - 21 days. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Trastuzumab (IV) Monotherapy - 21 days, 2022, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| HER2 positive metastatic breast cancer (MBC). | 1 |
| HER2 positive early breast cancer (EBC). | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab | |
| Sensitivity (+) | HER2-positive | Invasive Breast Carcinoma | Trastuzumab |